X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with SUVEN LIFE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUVEN LIFE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUVEN LIFE SANOFI INDIA/
SUVEN LIFE
 
P/E (TTM) x 33.6 19.1 175.8% View Chart
P/BV x 6.4 3.5 180.5% View Chart
Dividend Yield % 1.4 1.1 133.5%  

Financials

 SANOFI INDIA   SUVEN LIFE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
SUVEN LIFE
Mar-16
SANOFI INDIA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs4,560339 1,347.1%   
Low Rs4,400144 3,047.1%   
Sales per share (Unadj.) Rs1,028.539.2 2,620.6%  
Earnings per share (Unadj.) Rs129.07.5 1,728.4%  
Cash flow per share (Unadj.) Rs186.08.8 2,119.3%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.8 183.2%  
Book value per share (Unadj.) Rs753.649.0 1,538.1%  
Shares outstanding (eoy) m23.03127.28 18.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.46.2 70.8%   
Avg P/E ratio x34.732.4 107.4%  
P/CF ratio (eoy) x24.127.5 87.5%  
Price / Book Value ratio x5.94.9 120.6%  
Dividend payout %52.726.8 196.7%   
Avg Mkt Cap Rs m103,17430,732 335.7%   
No. of employees `0003.61.0 379.8%   
Total wages/salary Rs m3,592416 862.6%   
Avg. sales/employee Rs Th6,537.75,236.1 124.9%   
Avg. wages/employee Rs Th991.4436.5 227.1%   
Avg. net profit/employee Rs Th819.8995.5 82.3%   
INCOME DATA
Net Sales Rs m23,6864,995 474.2%  
Other income Rs m708194 365.9%   
Total revenues Rs m24,3945,189 470.1%   
Gross profit Rs m5,2811,233 428.4%  
Depreciation Rs m1,313167 785.3%   
Interest Rs m1554 27.7%   
Profit before tax Rs m4,6611,205 386.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691255 663.1%   
Profit after tax Rs m2,970950 312.7%  
Gross profit margin %22.324.7 90.4%  
Effective tax rate %36.321.2 171.4%   
Net profit margin %12.519.0 66.0%  
BALANCE SHEET DATA
Current assets Rs m15,6734,986 314.3%   
Current liabilities Rs m6,6781,042 640.7%   
Net working cap to sales %38.079.0 48.1%  
Current ratio x2.34.8 49.1%  
Inventory Days Days7661 124.6%  
Debtors Days Days2239 57.0%  
Net fixed assets Rs m8,0983,126 259.1%   
Share capital Rs m230127 180.9%   
"Free" reserves Rs m17,0883,717 459.7%   
Net worth Rs m17,3566,236 278.3%   
Long term debt Rs m0432 0.0%   
Total assets Rs m25,4008,079 314.4%  
Interest coverage x311.723.2 1,342.1%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.90.6 150.8%   
Return on assets %11.812.4 94.6%  
Return on equity %17.115.2 112.4%  
Return on capital %26.918.9 142.7%  
Exports to sales %24.587.5 28.0%   
Imports to sales %28.012.2 228.8%   
Exports (fob) Rs m5,8014,371 132.7%   
Imports (cif) Rs m6,627611 1,084.9%   
Fx inflow Rs m7,1454,666 153.1%   
Fx outflow Rs m6,846942 726.7%   
Net fx Rs m2993,724 8.0%   
CASH FLOW
From Operations Rs m3,226922 349.9%  
From Investments Rs m-1,555-619 251.1%  
From Financial Activity Rs m-1,818-698 260.3%  
Net Cashflow Rs m-147-396 37.1%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.5 28.8%  
Shareholders   15,184 37,287 40.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 22, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - NOVARTIS COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS